Virica Biotech and Ginkgo Bioworks have announced a strategic partnership aimed at improving AAV gene therapy production. Virica will provide a panel of its Viral Sensitizer Enhancers (VSETM) to Ginkgo for high-throughput AAV production screening, while Ginkgo will utilize its advanced screening platform to test VSEs directly in clients’ cell lines. This collaboration is expected to drive down manufacturing costs and make gene therapies more accessible, combining Ginkgo’s cutting-edge screening capabilities with Virica’s proprietary technology.

Read the Press Release